MAOA, a classical molecule of neurological origin, participates in regulating the dynamic balance of metabolites in tumor-associated immune cells and is expected to join the immune checkpoint family, which provides a rationale for targeting MAOA to ameliorate immune metabolic disorders associated with the TME. The gene discussed is MAOA; the disease is neoplasm.